| 000 | 01767 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250515091142.0 | ||
| 264 | 0 | _c20071219 | |
| 008 | 200712s 0 0 eng d | ||
| 022 | _a1528-0012 | ||
| 024 | 7 |
_a10.1053/j.gastro.2007.08.035 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPlevy, Scott | |
| 245 | 0 | 0 |
_aA phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. _h[electronic resource] |
| 260 |
_bGastroenterology _cNov 2007 |
||
| 300 |
_a1414-22 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aCD3 Complex _ximmunology |
| 650 | 0 | 4 |
_aCD4-Positive T-Lymphocytes _xpathology |
| 650 | 0 | 4 |
_aCD8-Positive T-Lymphocytes _xpathology |
| 650 | 0 | 4 |
_aColitis, Ulcerative _xdrug therapy |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aEndoscopy, Gastrointestinal |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 700 | 1 | _aSalzberg, Bruce | |
| 700 | 1 | _aVan Assche, Gert | |
| 700 | 1 | _aRegueiro, Miguel | |
| 700 | 1 | _aHommes, Daniel | |
| 700 | 1 | _aSandborn, William | |
| 700 | 1 | _aHanauer, Stephen | |
| 700 | 1 | _aTargan, Stephan | |
| 700 | 1 | _aMayer, Lloyd | |
| 700 | 1 | _aMahadevan, Uma | |
| 700 | 1 | _aFrankel, Matthew | |
| 700 | 1 | _aLowder, James | |
| 773 | 0 |
_tGastroenterology _gvol. 133 _gno. 5 _gp. 1414-22 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1053/j.gastro.2007.08.035 _zAvailable from publisher's website |
| 999 |
_c17441381 _d17441381 |
||